Leaflet IPRATROPIU/SALBUTAMOL AMRING 0.5mg / 2.5mg solution for inhalation by nebuliser

Product code:
W65228004
Quantity:
60
Indicated for:
nasal congestion; rhinitis
Route of administration:
inhalation
Substance:
ipratropium bromide + salbutamol (antimuscarinic bronchodilator + beta-2 adrenergic agonist)
ATC
R03AL02 — Respiratory system | Adrenergics, inhalants | Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids

Precautions:

Glaucoma warning

Use caution if you have glaucoma or increased eye pressure.

Anticholinergic effects

May cause dry mouth, constipation, urinary retention, or blurred vision.

Hyperglycemia

This medicine may increase blood sugar.

Elderly warning

Older people may have an increased risk of side effects.

Cardiac risk / QT prolongation / arrhythmias

This medicine may increase the risk of heart rhythm disturbances.

The combination of ipratropium bromide and salbutamol is used for the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma. Ipratropium bromide works by blocking muscarinic receptors, while salbutamol stimulates beta-2 adrenergic receptors, relaxing airway muscles.

The medication is administered as an aerosol or nebulizer solution, as directed by a doctor. It is important to follow the recommended dose to achieve the best results.

Side effects may include dry mouth, cough, tremors, or palpitations. In rare cases, severe allergic reactions or breathing difficulties may occur.

This combination is not recommended for patients with hypersensitivity to any of the components or severe cardiac conditions.

General data about IPRATROPIU/SALBUTAMOL AMRING 0.5mg / 2.5mg

Substance:
ipratropium bromide + salbutamol
Date of latest medicines list:
01-06-2026
Product code:
W65228004
Concentration:
0.5mg / 2.5mg
Pharmaceutical form:
solution for inhalation by nebuliser
Quantity:
60
Product type:
Generic medicine
Price:
182.95 RON
Prescription status:
P-6L — Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.

Marketing authorisation

Manufacturer:
CIPLA EUROPE NV - BELGIA
Holder:
AMRING FARMA S.R.L. - ROMANIA
Number:
12606/2019/04
Shelf life:
2 years-after packing for marketing;after the first opening-3 months

Concentrations available for ipratropium bromide + salbutamol

  • 0.5mg/2.5mg
  • 0.5mg/2.5mg/2.5ml